Sandoz signs deal to commercialize Herceptin biosimilar

30 April 2019

The self-proclaimed global leader in biosimilars is set to commercialize a copy of one of the world’s top-selling cancer drugs.

Sandoz, part of the Swiss pharma giant Novartis (NOVN: VX), has entered into an agreement to commercialize a proposed biosimilar of Herceptin (trastuzumab), which generated $7 billion in revenue for Roche (ROG: SIX) in 2018 but has declining sales due to increased competition. The US patent is due to expire in mid-June.

The drug that Sandoz is to market in the agreement with privately-held Taiwanese firm EirGenix is currently in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer tumors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK